ArticleCureus2025
Performance of the SARC-F (Strength, Assistance Walking, Rise From a Chair, Climb Stairs, and Falls) Questionnaire for Sarcopenia Screening in Patients With End-Stage Renal Disease on Hemodialysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe systematic screening of sarcopenia among patients with end-stage renal disease (ESRD) on hemodialysis (HD) has emerged as a critical component of comprehensive patient assessment and management. The SARC-F (Strength, Assistance walking, Rise from a chair, Climb stairs, and Falls) is a simple and widely used tool for sarcopenia screening across multiple populations; however, its diagnostic performance in HD remains uncertain. We aimed to evaluate the diagnostic performance of the SARC-F questionnaire for sarcopenia screening in HD patients.
methodsCross-sectional diagnostic accuracy study in Mexican patients with ESRD on HD. Sarcopenia was defined according to European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria: appendicular muscle mass, handgrip strength, and gait speed. The Spanish version of the SARC-F validated for Mexico was used; cut-off >4 points. Sensitivity, specificity, predictive values, receiver operating characteristic (ROC) curve, and area under the curve (AUC) were estimated.
resultsNinety-four patients were included (62.8% men; mean age 54±14 years). Sarcopenia prevalence was 8.5%. SARC-F >4 was observed in 17%. Diagnostic performance was poor: AUC 0.40 (95%CI 0.16-0.63; p=0.35), sensitivity 13% (95%CI, 2.2-47.1%), specificity 83% (95%CI, 73.2-89.1%), positive predictive value 6% (95%CI, 1.1-28.3%), and negative predictive value 91% (95%CI 82.6-95.6%).
conclusionsSARC-F showed poor diagnostic performance in HD patients. Its high specificity and negative predictive value suggest utility to rule out sarcopenia; combining SARC-F with objective measures of muscle mass and performance is recommended for more accurate screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.